Skip to content

Study · Not a test of the peptide alone · 2024

7 results

IDegLira for the real-world treatment of type 2 diabetes in Italy. Final results from the REX observational study.

Fadini GP, Buzzetti R, Pitocco D, Tortato E, Scatena A, Lamacchia O, Lastoria G, Simoni L, Consoli A

Diabetes, obesity & metabolism8 Feb 2024Cited by 7 (Europe PMC)

PMID38327240 (opens in a new tab)DOI10.1111/dom.15486 (opens in a new tab)PepBankPUB-38327240
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes switched to IDegLira, fasting blood glucose decreased significantly in both groups, more in the basal-bolus group.

    In plain wordsIn adults with type 2 diabetes switched to the IDegLira combination, fasting blood sugar fell in both groups, more in the basal-bolus group.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting blood glucose
    Study

    n = 358

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Fasting blood glucose and body weight also significantly decreased in both groups, although more in the BB group.
    2 context sentences
    Summary · context
    This was a non-interventional, multicentre, single-cohort, prospective study assessing the long-term glycaemic control in patients with T2D, who switched to IDegLira from a basal insulin ± glucose-lowering medication regimen with or without a bolus insulin component for approximately 18 months, cond…
    Summary · context
    The study included 358 patients with a mean age 67.2 years and diabetes duration of 15.7 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes switched to IDegLira, body weight decreased significantly in both groups, more in the basal-bolus group.

    In plain wordsIn adults with type 2 diabetes switched to the IDegLira combination, weight fell in both groups, more in the basal-bolus group.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n = 358

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Fasting blood glucose and body weight also significantly decreased in both groups, although more in the BB group.
    2 context sentences
    Summary · context
    This was a non-interventional, multicentre, single-cohort, prospective study assessing the long-term glycaemic control in patients with T2D, who switched to IDegLira from a basal insulin ± glucose-lowering medication regimen with or without a bolus insulin component for approximately 18 months, cond…
    Summary · context
    The study included 358 patients with a mean age 67.2 years and diabetes duration of 15.7 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes who switched from basal insulin to IDegLira, HbA1c fell by 1.19% at the end of observation.

    In plain wordsIn adults with type 2 diabetes who switched from basal insulin to the IDegLira combination, HbA1c fell by 1.19%.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change from IDegLira start, basal group
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c change
    −1.19%
    basal group

    Source sentences

    Summary
    HbA1c significantly decreased from IDegLira start to all study time points in the overall population (basal group -1.19%
    2 context sentences
    Summary · context
    This was a non-interventional, multicentre, single-cohort, prospective study assessing the long-term glycaemic control in patients with T2D, who switched to IDegLira from a basal insulin ± glucose-lowering medication regimen with or without a bolus insulin component for approximately 18 months, cond…
    Summary · context
    The study included 358 patients with a mean age 67.2 years and diabetes duration of 15.7 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes who switched from basal-bolus insulin to IDegLira, HbA1c fell by 0.60% at the end of observation.

    In plain wordsIn adults with type 2 diabetes who switched from basal-bolus insulin to the IDegLira combination, HbA1c fell by 0.60%.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change from IDegLira start, basal-bolus group
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c change
    −0.6%
    BB group

    Source sentences

    Summary
    HbA1c significantly decreased from IDegLira start to all study time points in the overall population (basal group -1.19%; BB group -0.60%
    2 context sentences
    Summary · context
    This was a non-interventional, multicentre, single-cohort, prospective study assessing the long-term glycaemic control in patients with T2D, who switched to IDegLira from a basal insulin ± glucose-lowering medication regimen with or without a bolus insulin component for approximately 18 months, cond…
    Summary · context
    The study included 358 patients with a mean age 67.2 years and diabetes duration of 15.7 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes switched to IDegLira, the proportion with HbA1c below 7% rose from 12.9% to 40.3% at 18 months.

    In plain wordsIn adults with type 2 diabetes switched to the IDegLira combination, the share with HbA1c below 7% rose from 12.9% to 40.3%.

    Peptide
    Liraglutide
    Outcome
    IncreasePatients with HbA1c below 7% at 18 months
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Patients with HbA1c <7% before
    12.9%
    IDegLira start
    Patients with HbA1c <7% at 18 months
    40.3%
    18 months

    Source sentences

    Summary
    Patients achieving HbA1c <7% levels increased from 12.9% (n = 43) to 40.3% (n = 110) at 18 months.
    2 context sentences
    Summary · context
    This was a non-interventional, multicentre, single-cohort, prospective study assessing the long-term glycaemic control in patients with T2D, who switched to IDegLira from a basal insulin ± glucose-lowering medication regimen with or without a bolus insulin component for approximately 18 months, cond…
    Summary · context
    The study included 358 patients with a mean age 67.2 years and diabetes duration of 15.7 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06HumanNot a test of Liraglutide aloneObservational studyOther

    In adults with type 2 diabetes switched to IDegLira, 14.3% of patients who completed had an intensification of treatment, mainly in the basal group.

    In plain wordsIn adults with type 2 diabetes on the IDegLira combination, 14.3% of those who finished needed stronger treatment, mostly in the basal group.

    Peptide
    Liraglutide
    Outcome
    Not applicableTreatment intensification
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Metabolic and weight

    Measurements

    Patients with intensification
    14.3%
    completed patients

    Source sentences

    Summary
    Overall, 14.3% of completed patients had an intensification of treatment (mainly in the basal group)
    2 context sentences
    Summary · context
    This was a non-interventional, multicentre, single-cohort, prospective study assessing the long-term glycaemic control in patients with T2D, who switched to IDegLira from a basal insulin ± glucose-lowering medication regimen with or without a bolus insulin component for approximately 18 months, cond…
    Summary · context
    The study included 358 patients with a mean age 67.2 years and diabetes duration of 15.7 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 07HumanNot a test of Liraglutide aloneObservational studyOther

    In adults with type 2 diabetes switched to IDegLira, 48.6% of patients who completed had a simplification of treatment, mainly in the basal-bolus group.

    In plain wordsIn adults with type 2 diabetes on the IDegLira combination, 48.6% of those who finished moved to simpler treatment, mostly in the basal-bolus group.

    Peptide
    Liraglutide
    Outcome
    Not applicableTreatment simplification
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Metabolic and weight

    Measurements

    Patients with simplification
    48.6%
    completed patients

    Source sentences

    Summary
    and 48.6% had a simplification of treatment (mainly in the BB group).
    2 context sentences
    Summary · context
    This was a non-interventional, multicentre, single-cohort, prospective study assessing the long-term glycaemic control in patients with T2D, who switched to IDegLira from a basal insulin ± glucose-lowering medication regimen with or without a bolus insulin component for approximately 18 months, cond…
    Summary · context
    The study included 358 patients with a mean age 67.2 years and diabetes duration of 15.7 years.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.